Lisa Li
Associate Director, Early-Stage Partnering Japan, Strategy & Portfolio Development Takeda Pharmaceutical
Search & Evaluation professional at Takeda with 1+ year of experience evaluating external neuroscience assets across Japan/APAC, from early discovery through clinical proof-of-concept, to support pipeline growth. A stem cell biologist by training, with 7+ years in academic research and 7+ years in big pharma R&D, with expertise in CNS disease modeling using iPSCs and gene editing technologies. Long term, aiming to take on broader leadership roles at the intersection of science, business, and innovation—spanning business development, strategy, partnerships, and investment—to help advance high-impact biotech through collaboration across industry, academia, and the startup ecosystem. Currently pursuing Global MBA at University of Manchester.
Seminars
- Which CNS indications and targets hold the greatest promise for investable disease‑modifying therapies?
- What stage and type of data are needed to confidently support safety, target engagement, and MoA of new targets under evaluation?
- Do you prioritize new modalities aligned with in‑house expertise, or are you open to partnering with specialists in novel modalities?
